Nonalcoholic fatty liver disease: new treatments by Hardy T et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a  
Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Hardy T, Anstee QM, Day CP. 
Nonalcoholic fatty liver disease: new treatments. 
Current Opinion in Gastroenterology 2015, 31(3), 175-183. 
 
Copyright: 
© 2015 Wolters Kluwer Health, Inc. 
This is an open-access article distributed under the terms of the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 License, where it is permissible to download and share the work 
provided it is properly cited. The work cannot be changed in any way or used 
commercially. http://creativecommons.org/licenses/by-nc-nd/4.0 
 
Link to the published article: 
http://dx.doi.org/10.1097/MOG.0000000000000175 
 
Date deposited:   
30/04/2015 
 
 
REVIEW CURRENTOPINION Nonalcoholic fatty liver disease: new treatments Copyrig
0267-1379 Copyright  2015 WolteTimothy Hardy, Quentin M. Anstee, and Christopher P. DayPurpose of review
Nonalcoholic fatty liver disease is the most common cause of liver dysfunction in the western world
because of its close association with obesity, insulin resistance and dyslipidaemia. Nonalcoholic
steatohepatitis (NASH) is a particular health concern due to the increased morbidity and mortality
associated with progressive disease. At present, without specific targeted pharmacological therapies, the
mainstay of therapy remains weight loss through dietary modification and lifestyle change; thus, the
purpose of this review is to summarize the recent evidence for current and emerging therapies in NASH.
Recent findings
Some existing medications, including pioglitazones and angiotensin receptor antagonists, may be
repurposed to help treat this condition. Vitamin E may improve histology in NASH, but safety issues limit its
use. Recently, a number of novel agents specifically targeting nonalcoholic fatty liver disease pathogenesis
have entered clinical trials, including the farnesoid X receptor agonist obeticholic acid, which has shown
significant histological improvements in steatohepatitis and fibrosis.
Summary
Diet/lifestyle modification remains the mainstay of treatment. For patients with NASH and advanced
fibrosis, current liver-directed pharmacotherapy with vitamin E and pioglitazone offer some benefits;
obeticholic acid appears promising and is currently being tested. Comorbidities must be diagnosed and
treated; cardiovascular disease remains a primary cause of death in these patients.
Keywords
nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, treatmentLiver ResearchGroup, Institute of Cellular Medicine,The Medical School,
Newcastle University, Newcastle-Upon-Tyne, UK
Correspondence to Professor Christopher P. Day, Pro-Vice Chancellor
and Provost of Medical Sciences, Medical Sciences Faculty Office, TheINTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is the most
common cause of liver dysfunction in the western
world [1] because of its close association with
obesity, insulin resistance and dyslipidaemia; it is
therefore considered the hepatic manifestation of
the metabolic syndrome. A particular health con-
cern is patients with nonalcoholic steatohepatitis
(NASH) with accompanying hepatocellular injury
that can lead to progressive liver fibrosis, cirrhosis
and hepatocellular carcinoma (HCC) as well as
increased cardiovascular risk [1]. At present, there
is no approved therapy for NASH and the optimal
treatment remains uncertain; effective therapies are
thus a research priority to reduce the anticipated
burden of liver disease.Medical School, Newcastle University, Framlington Place, Newcastle-
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The rationale for therapeutic approaches is centred
on the concept that while simple steatosis has not
been associated with morbidity, NASH is associated
with a more than 10-fold increased risk of liver-
related death (2.8 vs. 0.2%) and a doubling ofht © 2015 Wolters Kluwe
rs Kluwer Health, Inc. All rights resecardiovascular risk [2]; at the time of diagnosis,
25–33% of patients with NASH have advanced fib-
rosis, including cirrhosis [3,4]. After adjustment for
confounders, NASH has a similar fibrotic potential
to that of chronic hepatitis C [3,4]. Pooled data
suggest that about 21% of patients with NASH will
have some regression of fibrosis while 38% of
patients will progress over 5.3 years’ follow-up [3],
results that have recently been confirmed in a dual-
biopsy Northern European population [5
&&
].r Health, Inc. All rights reserved.
rved. www.co-gastroenterology.com
KEY POINTS
 Diet and lifestyle modification, with weight loss, remain
the mainstay of treatment for NAFLD.
 Vitamin E and pioglitazone offer some benefit in
selected cases (NASH and bridging fibrosis), although
these must be balanced with potential adverse effects.
 Obeticholic acid may provide the first liver-targeted
therapy for NASH.
 Cardiovascular disease must be diagnosed and treated.
LiverLifestyle modifications
Weight reduction is recommended as the initial step
in management of NASH. Pharmacological agents
such as orlistat may help achieve weight loss; how-
ever, whether these confer additional independent
benefit beyond that due to weight loss is unclear
[6,7]. Lifestyle modification therefore remains the
primary therapy for weight reduction, particularly
in the absence of approved pharmacotherapy; it
encompasses diet, physical activity (aerobic and
resistance) and behavioural change, or a combi-
nation of all three. Trial evidence shows that weight
reduction more than 7% sustained over 48 weeks is
associated with significant reduction in histological
severity of NASH [8]. A systematic review of the
available evidence for lifestyle modifications in
NAFLD has recently been conducted [9]. Less than
50% of patients achieve the necessary weight loss
goal of more than 7% in the trial setting [8], and
many have questioned the sustainability of this type
of intervention [10]. Resistance training, which is
less burdensome on the cardiovascular system, Copyright © 2015 Wolters Kluwer 
Table 1. Summary of agents tested in nonalcoholic steatohepatiti
Benefit Agent Comment
Potential benefit Pioglitazone Improves components of the NA
Vitamin E Significant improvement in histo
No clear benefit Metformin No effect on histology [16,17].
Statins
Atorvastatin No histological data, but impro
Simvastatin No effect on histology or liver e
UDCA Histological data lacking, four R
PUFAs No histological improvement in
Unclear benefit Angiotensin
receptor
blockers
Improvements in histology (necr
Pentoxyfylline Improvement in NASH activity s
MI, myocardial infarction; NAFLD, nonalcoholic fatty liver disease; NAS, NAFLD ac
acids; RCT, randomized controlled trial; UDCA, ursodeoxycholic acid.
176 www.co-gastroenterology.comshares the metabolic improvements seen in more
strenuous aerobic exercise andmay bemore sustain-
able [11]. Nevertheless, in themany patients that fail
to implement lifestyle changes or have advanced
disease (bridging fibrosis) on index biopsy, specific
liver-directed pharmacotherapy may be needed. No
drugs are currently licensed specifically for treating
NASH; there is an urgent need for well designed
randomized controlled trials (RCTs) with appropri-
ate endpoints to narrow this gap. Table 1 [12–21,
22
&&
,23–25] summarizes the current evidence for
therapies in NASH.Therapies of potential value for the treatment
of nonalcoholic steatohepatitis
Very few large RCTs have been published on which
evidence-based treatment for NASH is recom-
mended. Therapies with potential benefit in NASH
include thiazolidinediones (TZDs) and vitamin E.
Thiazolidinediones
The most extensively studied and for which the best
data are available is for the use of TZDs in the
treatment of NASH [4]. Central to their action is
their ability to ameliorate insulin resistance and
promote fatty acid uptake peripherally [26]; free
fatty acids are thus diverted away from the liver
towards adipose tissue.
TZDs activate the master adipocyte differen-
tiation regulator, peroxisome proliferator-activated
receptor (PPAR)g, allowing transdifferentiation of
preadipocytes into insulin-sensitive, fat-storing adi-
pocytes [27–29]. Interestingly, PPARg ligands also
attenuate liver fibrosis by suppressing the transdif-
ferentiation of hepatic stellate cells into activatedHealth, Inc. All rights reserved.
s
S score [12]. Increased risk of bladder cancer and MI [13,14].
logical lesions [12]. However, may increase all-cause mortality [15].
ves liver enzymes and radiological steatosis [18,19].
nzymes [20].
CTs showed no effect on liver enzymes [21].
activity [22&&], but reduction in steatosis radiologically [23].
oinflammation and fibrosis) but study limited to seven patients [24].
core, but not in fibrosis stage. Study limited to 55 patients [25].
tivity score; NASH, nonalcoholic steatohepatitis; PUFAs, polyunsaturated fatty
Volume 31  Number 3  May 2015
Nonalcoholic fatty liver disease Hardy et al.myofibroblasts suggesting an additional direct hep-
atoprotective effect [30–32]. They also have anti-
inflammatory effects [33] and increase circulating
adiponectin, an antisteatogenic and insulin-sensi-
tizing adipokine [34,35].
The largest multicentre RCT to date included
247 nondiabetic noncirrhotic patients with biopsy-
proven NASH who received pioglitazone (30mg/
day), vitamin E (800 IU/day) or placebo for 96weeks.
Histological improvement that included a reduction
of two points in the NAFLD activity score (NAS) with
no worsening of fibrosis was the primary endpoint;
pioglitazone failed to achieve a statistically signifi-
cant effect compared with placebo [12]. However, it
did significantly improve each individual com-
ponent of the NAS score (steatosis, lobular inflam-
mation and ballooning). When the analysis was
confined to patients with definite steatohepatitis
on their index biopsy, pioglitazone achieved the
primary endpoint. Several other well conducted
trials have shown improvements in steatosis, nec-
roinflammation and ballooning [36–38]; however,
to date, no study has shown a definite improvement
in fibrosis, which is not surprising given the rela-
tively short follow-up periods in most studies.
TZD-mediated effects seem to be abrogated upon
treatment discontinuation; at 3 months, alanine
transaminase (ALT) and homeostatic model assess-
ment return to baseline. In seven out of nine
patients who discontinued medication, recurrent
NASHwas seen at a 48-week posttherapy biopsy [39].
Unfortunately, side-effects (weight gain [40],
bone loss/fracture risk [41], increased risk of myo-
cardial infarction with rosiglitazone [13], increased
risk of bladder cancer with pioglitazone [14]) and
the possible need for long-term therapy [39] have
limited widespread acceptance, with rosiglitazone
withdrawn from the market in most countries. Pio-
glitazone remains available and current guidelines
suggest consideration in older patients with biopsy-
proven advanced fibrosis that are unable to adopt or
maintain lifestyle intervention, with continued
metabolic risk factors; caution is required in patients
with diabetes or those with heart failure [4,42].
Vitamin E
Apart from targeting aspects of the metabolic syn-
drome that may have beneficial liver effects, liver-
specific therapies have also been investigated in
NASH. The role of oxidative stress in disease patho-
genesis, in particular, has initiated several studies of
antioxidants, primarily vitamin E. Vitamin E con-
sists of eight tocopherols; a-tocopherol is the most
active. Its presence in the phospholipid bilayer of
cell membranes allows prevention of the nonenzy-
matic oxidation of cell constituents by free radicals. Copyright © 2015 Wolters Kluwe
0267-1379 Copyright  2015 Wolters Kluwer Health, Inc. All rights reseVitamin E may also inhibit profibrotic activity
[43,44] and downregulates nuclear factor (NF)-kB-
mediated inflammatory pathways in the liver [45].
Preclinical in-vitro and in-vivo studies have shown
that in two fibrosismodels, vitamin E can ameliorate
liver injury blocking both apoptotic pathways and
mitochondrial toxicity [46,47].
The Pioglitazone versus Vitamin E versus
Placebo for the Treatment of Nondiabetic Patients
with Nonalcoholic Steatohepatitis (PIVENS) trial,
described earlier, is the largest andmost recent study
comparing pioglitazone and vitamin E at 800 IU/day
to placebo in nondiabetic, noncirrhotic patients; it
reported that vitamin E improved all histological
lesions in NAFLD except for fibrosis, and patients
taking vitamin E had a greater than two-point
improvement on NAS score significantly more often
compared with placebo [12]. A pilot study suggested
that pioglitazone and vitamin E are superior to
pioglitazone alone but the study was not appropri-
ately powered [48]. The positive and encouraging
results seen in adult NAFLD may not extrapolate to
paediatric NAFLD. The largest trial of vitamin E in
paediatric NAFLD, the Treatment of NAFLD in Chil-
dren (TONIC) trial, randomly assigned children and
adolescents to receive vitamin E (800 IU/day) vs.
metformin (1 g/day) or placebo for 2 years. Vitamin
E significantly improved hepatocyte ballooning but
not lobular inflammation, steatosis nor fibrosis. The
primary endpoint of reduction in ALT levels, more
often than placebo, was not met [16].
The results of these studies with vitamin E need
to be balanced against the emerging body of data
that vitamin E may increase all-cause mortality: an
additional 39 deaths per 10000 people for those on
high-dose (400 IU/day) vitamin E in a dose-depend-
ent manner starting at 150 IU/day, much less than
the doses trialled in NASH [15]. Furthermore, vita-
min E therapy may be associated with an increase in
prostate cancer in men above 50 years old according
to a large study of 35000 patients, and a 20%
increased risk of haemorrhagic stroke [49,50]. In
light of these risks, the current American Associ-
ation for the Study of Liver Diseases guidelines
recommend that use of vitamin Emay be considered
in nondiabetic adults with NASH, but not diabetic
patients or children [28].
Therapies with no clear benefit
Several well recognized pharmacotherapies have
been investigated in NASH; currently, they are not
recommended for its treatment.
Metformin
Although metformin initially seemed promising in
animal models of NASH [51], no histologicalr Health, Inc. All rights reserved.
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Liverimprovement in steatohepatitis has been shown in
RCTs in adult and paediatric NASH [16,17]. Low-
dose metformin could not mitigate the weight gain
associated with rosiglitazone in a recent RCT [52],
although its effect seems likely to be through weight
loss in the small number of treated patients [53]. As
it has no effect on histology, metformin is not
currently recommended as a targeted treatment
for NAFLD.
Statins
Statins are well recognized in the treatment of dys-
lipidaemia, but their use as a specific treatment for
NAFLD is not well evidenced. Data from the Greek
Atorvastatin and Coronary Heart Disease Evaluation
study did, however, demonstrate a fall in ALT levels
with atorvastatin [19] and the St Francis Heart Study
showed a reduction in steatosis radiologically with
20mg daily of atorvastatin combined with vitamins
C and E [18]. There are, however, no histological
data currently available to support the use of ator-
vastatin for NAFLD. Although histological data exist
for simvastatin, in a trial of 10 patients with biopsy-
proven NASH, there was no statistically significant
improvement in serum liver enzymes, hepatic stea-
tosis, necroinflammatory activity or stage of fibrosis
within or between treatment and placebo [20]. How-
ever, its use to reduce cardiovascular risk in patients
with NAFLD is clear and there is no evidence to
suggest that patients with NAFLD are at increased
risk of statin-related liver injury [54].
Ursodeoxycholic acid
Ursodeoxycholic acid (UDCA), by preventing apop-
tosis and downregulating inflammatory pathways,
is an example of a potential cytoprotective agent
investigated in NASH. The largest study to date
comparing UDCA and placebo showed an unantici-
pated improvement in the placebo arm, making the
effect of the drug hard to interpret [55]. A Cochrane
review of four randomized trials using UDCA
showed no significant improvement in liver func-
tion tests and histological data were lacking [21].
Until there is evidence of clear histological benefit,
UDCA cannot be currently recommended for NASH.
Polyunsaturated fatty acids
Despite preliminary data from small studies
suggesting that v-3 polyunsaturated fatty acid
supplementation reduces liver fat content [23], a
large trial testing twodosesof ethyl-eicosapentaenoic
acid did not show any histological efficacy [22
&&
].
Therapies with unclear benefit
Some agents tested in NASH have robust preclinical
data, but are yet to be investigated in large RCTs. Copyright © 2015 Wolters Kluwer 
178 www.co-gastroenterology.comAngiotensin receptor blockers
Angiotensin receptor blockers are well established in
the treatment of hypertension, a second key com-
ponent of the metabolic syndrome. Experimental
work has clearly shown that angiotensin II promotes
survival of hepatic myofibroblasts by activation of
IkB kinase-mediated phosphorylation of NF-kB sub-
unit RelA [56]. A small pilot study of seven patients
with NASH treated with losartan for 48 weeks
showed improvements in necroinflammation and
fibrosis [24]. Larger studies examining the utility of
this agent are ongoing.
Pentoxifylline
Pentoxifylline (PTX) is a tumour necrosis factor-a
agonist and reduces production of oxygen-free
radicals [57]. Animal models have also suggested
an antifibrotic effect together with significantly
reducing steatohepatitis [58]. The largest and most
recent RCT published in 2011 included 55 patients
with NASH receiving PTX or placebo; patients on
PTX showed a mean 1.6-point improvement on the
NAS score vs. 0.1 point in placebo. Although not
significant, there was a slight improvement in fib-
rosis [25]. Before PTX can be recommended as
primary therapy, larger and more compelling data
are warranted.Novel approaches
New therapies with strong experimental evidence
are currently being trialled in human NASH, and
may provide hope of a targeted pharmacotherapy;
these are summarized in Table 2 [59–66].
Caspase inhibition (GS-9450)
Preclinical models have shown that hepatocyte
apoptosis is a hallmark of NASH [67], the extent
of which correlates with disease severity. In a recent
phase-2 placebo-controlled trial, 124 patients with
histologically characterized NASH were randomized
to once-daily placebo or GS-9450, a selective caspase
inhibitor, at varying dosages for 4 weeks. In the
highest dose group (40mg), both ALT and cytoker-
atin-18 fragment levels improved but only ALT
reached significance; GS-9450 was safe and well
tolerated [68].
PPAR agonists (GFT-505)
GFT-505 is a dual PPARa and PPARd agonist that in
animal models of dietary-induced NASH has shown
a reduction in steatosis, inflammation and pro-
inflammatory genes; interestingly, GFT-505 has also
demonstrated antifibrotic properties, independent
of metabolic abnormalities [69
&
]. Human studies
have shown that GFT-505 improves liver functionHealth, Inc. All rights reserved.
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Table 2. Novel agents currently being tested in, or completed, phase 2 trials
Agent Action Effect on NASH pathogenesis ClinicalTrials.gov identifier
GS-9450 Caspase inhibition Prevents apoptosis NCT00740610 [59]
GFT-505 Dual PPARa/d agonist Hepatic glucose utilization, lipoprotein metabolism
and anti-inflammatory effects
NCT01694849 [60]
Obeticholic acid FXR agonist Promotes insulin sensitivity, decreases hepatic
gluconeogenesis and circulating triglycerides
NCT01265498 [61]
Cenicriviroc CCR2/CCR5 antagonist Interferes with recruitment of monocytes,
macrophages and HSCs upon liver injury
NCT02217475 [62]
Liraglutide GLP-1 agonist Induces insulin secretion, reduces glucagon secretion NCT01237119 [63]
Sitagliptin DPP-IV inhibitors Prevents degradation of GLP-1 NCT01963845 [64]
GS-6624 (simtuzumab) Anti-LOXL-2 antibodies Inhibits formation and repair of extracellular matrix NCT01672879 [65]/
NCT01672866 [66]
CCR, C–C chemokine receptor; DPP-IV, dipeptidyl peptidase-4; FXR, farnesoid X receptor; GLP-1, glucagon-like peptide-1; HSC, hepatic stellate cell; LOXL-2, lysyl
oxidase-like 2; NASH, nonalcoholic steatohepatitis; PPAR, peroxisome proliferator-activated receptor.
Clinicaltrials.gov accessed on 28 January 2015.
Nonalcoholic fatty liver disease Hardy et al.tests, dyslipidaemia and insulin sensitivity in obese,
insulin-resistant patients [70,71]. A phase 2b RCT is
now ongoing based on these encouraging results
[60].
Farnesoid X receptor agonists (obeticholic
acid)
Bile acids act as metabolic signalling molecules,
aiding dietary lipid absorption, and are involved
in cholesterol homeostasis; they are reabsorbed into
the enterohepatic circulation and direct hepatic
triglyceride and glucose metabolism. They activate
nuclear hormone receptor farnesoid X receptor
(FXR) and the G protein-coupled cell surface recep-
tor transmembrane G protein-coupled receptor,
which inhibit hepatic de-novo lipogenesis, hepatic
gluconeogenesis and glycogenolysis and improve
insulin sensitivity. In animal studies, FXR activation
has anti-inflammatory actions, partly by inhibiting
NF-kB [72,73]. In-vivo evidence exists for a protec-
tive effect of FXR agonists against liver inflam-
mation and fibrosis in the methionine–choline-
deficient model of NASH [74]. Thus, obeticholic
acid, an FXR agonist, was studied in a small pilot
trial of 23 diabetic patients with NAFLD. Patients
received 6 weeks of the study drug at either 25mg or
50mg daily or placebo. Patients on the study drug
lost weight with an associated fall in serum g-glu-
tamyl transferase and an improvement in the non-
invasive Enhanced Liver Fibrosis panel observed
more often than in the placebo group [75
&
].
A 72-week trial of 273 patients with NASH
randomized to obeticholic acid or placebo has
recently reported evidence of significant reductions
in histologically defined endpoints including degree
of steatosis, grade of inflammation/ballooning
degeneration and stage of fibrosis [76
&&
]. These Copyright © 2015 Wolters Kluwe
0267-1379 Copyright  2015 Wolters Kluwer Health, Inc. All rights resechanges were accompanied by mild weight loss
and improved clinical biochemistry parameters, also
consistent with reduced liver injury. However, a rise
in total cholesterol and a disadvantageous change in
high-density lipoprotein/low-density lipoprotein
ratio were also observed with obeticholic acid treat-
ment [76
&&
]. Despite this, the agent remains one of
the first in which robust, beneficial changes in liver
histology have been identified.
Other promising agents with anti-inflamma-
tory, antifibrotic or insulin-sensitizing properties
currently in development or undergoing testing in
RCTs in NASH include dual C–C chemokine recep-
tor 2/5 antagonists, glucagon-like peptide-1 ago-
nists, dipeptidyl peptidase-4 inhibitors and anti-
lysyl oxidase-like 2 antibodies (simtuzumab).
Hepatocellular carcinoma
Obesity and diabetes have been well established as
risk factors for HCC [77–79]. Recently, HCC has
been linked to NAFLD [80], and there is mounting
evidence that the same PNPLA3 genetic variant
(I148M, rs738409) that has long been associated
with progressive NAFLD also confers an increased
risk of NAFLD-HCC [81,82
&
]. The prevalence of HCC
in cirrhotic NAFLD remains undetermined [83],
although steatohepatitis was identified as the under-
lying aetiology in 24% of patients in a series of HCC
surpassing all other causes of chronic liver disease
[70] and this trend is set to increase further. In the
United Kingdom, a more than 10-fold increase in
NAFLD-associated HCC has been observed from
2000 to 2010, with NAFLD-HCC accounting for
34.8% of all HCC cases [84]. It is increasingly rec-
ognized that NAFLD is a cause of noncirrhotic HCC.
A recent Japanese cross-sectional study analyzed
87 cases of HCC occurring in patients withr Health, Inc. All rights reserved.
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Liverhistologically characterized steatohepatitis; no
established cirrhosis was demonstrated in 43 cases
[85]. Most worryingly, HCC has been reported in
patients even without steatohepatitis [86]. An
analysis of a US insurance claims database found
NAFLD was the leading condition associated with
HCC, with cirrhosis reported in just 46% of these
cases [87].
Adipose tissue expansion and subsequent release
of proinflammatory cytokines/adipokines [88,89]
and lipotoxicity [90] together promote insulin resist-
ance; hyperinsulinaemia results in increased bio-
availability of insulin growth factor-1, which
further stimulates cellular proliferation and inhibits
apoptosis [91]. Metformin, a biguanide that activates
adenosine monophosphate-activated protein kinase
and has antiproliferative effects has been shown to
inhibithepatocyteproliferationand inducecell-cycle
arrest in hepatoma cell lines [92]. Consequently,
targeting insulin resistancewithmetformin has been
investigated in observational and case–control
studies of HCC [93,94]. Among patients with type
2 diabetes mellitus, metformin was associated with
an estimated 62% reduction in the risk of HCC in a
recent meta-analysis (odds ratio, 0.38; 95% confi-
dence interval, 0.24–0.59) [95]. However, the ability
of metformin to protect against NASH-associated
carcinogenesis is not firmly established as human
data are retrospective and do not mitigate against
treatment assignment bias.
There is biological plausibility that statins reduce
cancer risk via HCC-specific (Myc inactivation) Copyright © 2015 Wolters Kluwer 
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180 www.co-gastroenterology.com[96,97] aswell asantiproliferative,proapoptotic, anti-
angiogenic, immunomodulatory and antiinfective
mechanisms [98–100]. A recentmeta-analysis exam-
ining over 1.4 million patients found results to be
heterogeneous [101
&
]. Data from observational stud-
ies indicated that statins lowered the risk of HCC in
various patient populations; however, no clear
benefit was found when only rigorously conducted
RCTs were included in the analysis [101
&
].Bariatric surgery
Surgical weight loss interventions have been inves-
tigated in the treatment of NAFLD; the most com-
mon procedures tested are laparoscopic adjustable
gastric banding and Roux-en-Y gastric bypass. Sev-
eral uncontrolled studies have reported that bariat-
ric surgery has shown to produce significant weight
loss and may be beneficial for the treatment of
NAFLD [102,103], but the lack of RCTs precluded
this conclusion in a Cochrane review [104]. Never-
theless, a recent study reported that on postbariatric
biopsy of 160 patients, steatosis resolved in 75% and
steatohepatitis resolved in 90%. Fibrosis of any
grade resolved in 53% of patients, with even bridg-
ing fibrosis resolved in 29% of patients [105]. The
effects of bariatric surgery on steatosis and balloon-
ing appear durable in a 5-year sequential biopsy
study, but fibrosis worsened significantly, although
more than 95% of patients had a fibrosis score F1 or
less at 5 years [106]. Clearly, surgical intervention is
not a panacea for all patients with NASH, and moreHealth, Inc. All rights reserved.
fication
ss
olic syndrome
nce
ce
s
c)
Dyslipidaemia
Statin (safe, CVD risk
reduction)
cotherapy
-cirrhotic adults*
h aggressive NASH*
Orlistat
*Consider individualized risk/benefit
lic steatohepatitis using currently available agents.
Volume 31  Number 3  May 2015
Nonalcoholic fatty liver disease Hardy et al.robust data fromRCTs are needed before recommen-
dations can be made.CONCLUSION
Despite its prevalence and rising incidence, NAFLD
is marked by substantial interpatient variability in
prognosis and continues to lack the breadth of
therapeutic research and development shared by
other causes of chronic liver disease. Although
major advances have been made in understanding
pathogenesis and also identification of genetic
modifiers of liver injury extending beyond simple
steatosis including PNPLA3 and TM6SF2
[81,107,108
&&
], these advances have not yet been
fully capitalized upon and so we lack effective phar-
macotherapy. Diet and lifestyle modification
remain the mainstay of treatment. For patients with
NASH and advanced fibrosis, current liver-directed
pharmacotherapy with vitamin E and pioglitazone
offer some benefits in selected cases. Figure 1 pro-
vides a schematic of treatment, once the diagnosis of
NASH has been made. However, the beneficial
effects of these therapies must be balanced with
the potential adverse effects, limiting their wide-
spread use. Coexisting comorbidity must be diag-
nosed and treated because CVD remains primary
cause of death in these patients. The new agents
currently in trial provide the first hope of effective,
targeted pharmacotherapy in this field.
Acknowledgements
None.
Financial support and sponsorship
Q.M.A. is the recipient of a Clinical Senior Lectureship
Award from the Higher Education Funding Council for
England (HEFCE). T.H. is the recipient of a Clinical
Research Fellowship Award from the Medical Research
Council (MRC), UK.
Conflicts of interest
Q.M.A. has received research grant funding from Glaxo-
SmithKline, honoraria for lecturing from Abbott Labora-
tories and has performed consultancy for GENFIT,
Synageva, NewGene and Acuitas Medical.
REFERENCES AND RECOMMENDED
READING
Papers of particular interest, published within the annual period of review, have
been highlighted as:
& of special interest
&& of outstanding interest1. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus,
cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013;
10:330–344.
2. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients
with NAFLD and elevated liver enzymes. Hepatology 2006; 44:865–873. Copyright © 2015 Wolters Kluwe
0267-1379 Copyright  2015 Wolters Kluwer Health, Inc. All rights rese3. Argo CK, Caldwell SH. Epidemiology and natural history of nonalcoholic
steatohepatitis. Clin Liver Dis 2009; 13:511–531.
4. Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/
NASH based on the EASL 2009 special conference. J Hepatol 2010;
53:372–384.
5.
&&
McPherson S, Hardy T, Henderson E, et al. Evidence of NAFLD progression
from steatosis to fibrosing-steatohepatitis using paired biopsies: implications
for prognosis and clinical management. J Hepatol 2014. doi: http://
dx.doi.org/10.1016/j.jhep.2014.11.034.
Largest paired-biopsy cohort to date (108 patients) demonstrating progression to
fibrosing steatohepatitis from steatosis.
6. Harrison SA, Fecht W, Brunt EM, et al. Orlistat for overweight subjects with
nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology
2009; 49:80–86.
7. Zelber-Sagi S, Kessler A, Brazowsky E, et al. A double-blind randomized
placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver
disease. Clin Gastroenterol Hepatol 2006; 4:639–644.
8. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing
the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010;
51:121–129.
9. Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of
nonalcoholic fatty liver disease in adults: a systematic review. J Hepatol
2012; 56:255–266.
10. Franz MJ, VanWormer JJ, Crain AL, et al. Weight-loss outcomes: a systematic
review and meta-analysis of weight-loss clinical trials with a minimum 1-year
follow-up. J Am Diet Assoc 2007; 107:1755–1767.
11. Hallsworth K, Fattakhova G, Hollingsworth KG, et al. Resistance exercise
reduces liver fat and its mediators in nonalcoholic fatty liver disease inde-
pendent of weight loss. Gut 2011; 60:1278–1283.
12. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or
placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362:1675–
1685.
13. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with
rosiglitazone: a meta-analysis. J Am Med Assoc 2007; 298:1189–1195.
14. Neumann A, Weill A, Ricordeau P, et al. Pioglitazone and risk of bladder
cancer among diabetic patients in France: a population-based cohort study.
Diabetologia 2012; 55:1953–1962.
15. Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage
vitamin E supplementation may increase all-cause mortality. Ann Intern Med
2005; 142:37–46.
16. Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or
metformin for treatment of nonalcoholic fatty liver disease in children and
adolescents: the TONIC randomized controlled trial. J Am Med Assoc 2011;
305:1659–1668.
17. Haukeland JW, Konopski Z, Eggesbo HB, et al. Metformin in patients with
nonalcoholic fatty liver disease: a randomized, controlled trial. Scand J
Gastroenterol 2009; 44:853–860.
18. Foster T, Budoff MJ, Saab S, et al. Atorvastatin and antioxidants for the
treatment of nonalcoholic fatty liver disease: the St Francis Heart Study
randomized clinical trial. Am J Gastroenterol 2011; 106:71–77.
19. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term
statin treatment for cardiovascular events in patients with coronary heart
disease and abnormal liver tests in the Greek Atorvastatin and Coronary
Heart Disease Evaluation (GREACE) Study: a posthoc analysis. Lancet
2010; 376:1916–1922.
20. Nelson A, Torres DM, Morgan AE, et al. A pilot study using simvastatin in the
treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled
trial. J Clin Gastroenterol 2009; 43:990–994.
21. Orlando R, Azzalini L, Orando S, et al. Bile acids for nonalcoholic fatty liver
disease and/or steatohepatitis. Cochrane Database Syst Rev 2007;
(1):CD005160.
22.
&&
Sanyal AJ, Abdelmalek MF, Suzuki A, et al. No significant effects of ethyl-
eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis
in a phase 2 trial. Gastroenterology 2014; 147:377–384.
Two hundred forty three patients assigned to placebo, low or high-dose ethyl-
eicosapentaenoic acid-E with no significant effects on histology or biochemistry.
23. Argo CK, Patrie JT, Lackner C, et al. Effects of n-3 fish oil on metabolic and
histological parameters in NASH: a double-blind, randomized, placebo-
controlled trial. J Hepatol 2015; 62:190–197.
24. Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of an
angiotensin II receptor antagonist in patients with nonalcoholic steatohepa-
titis. Hepatology 2004; 40:1222–1225.
25. Zein CO, Yerian LM, Gogate P, et al. Pentoxifylline improves nonalcoholic
steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011;
54:1610–1619.
26. Frohnert BI, Hui TY, Bernlohr DA. Identification of a functional peroxisome
proliferator-responsive element in the murine fatty acid transport protein
gene. J Biol Chem 1999; 274:3970–3977.
27. Tontonoz P, Hu E, Graves RA, et al. mPPAR gamma 2: tissue-specific
regulator of an adipocyte enhancer. Genes Dev 1994; 8:1224–1234.
28. Sears IB, MacGinnitie MA, Kovacs LG, et al. Differentiation-dependent
expression of the brown adipocyte uncoupling protein gene: regulation by
peroxisome proliferator-activated receptor gamma. Mol Cell Biol 1996;
16:3410–3419.r Health, Inc. All rights reserved.
rved. www.co-gastroenterology.com 181
Liver29. Kim JB, Spiegelman BM. ADD1/SREBP1 promotes adipocyte differentiation
and gene expression linked to fatty acid metabolism. Genes Dev 1996;
10:1096–1107.
30. Galli A, Crabb DW, Ceni E, et al. Antidiabetic thiazolidinediones inhibit
collagen synthesis and hepatic stellate cell activation in vivo and in vitro.
Gastroenterology 2002; 122:1924–1940.
31. Marra F, Efsen E, Romanelli RG, et al. Ligands of peroxisome proliferator-
activated receptor gamma modulate profibrogenic and proinflammatory
actions in hepatic stellate cells. Gastroenterology 2000; 119:466–478.
32. Miyahara T, Schrum L, Rippe R, et al. Peroxisome proliferator-activated recep-
tors and hepatic stellate cell activation. J Biol Chem 2000; 275:35715–
35722.
33. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, et al. Macrophage-specific
PPARgamma controls alternative activation and improves insulin resistance.
Nature 2007; 447:1116–1120.
34. Yu JG, Javorschi S, Hevener AL, et al. The effect of thiazolidinediones on
plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.
Diabetes 2002; 51:2968–2974.
35. Tonelli J, Li W, Kishore P, et al. Mechanisms of early insulin-sensitizing effects
of thiazolidinediones in type 2 diabetes. Diabetes 2004; 53:1621–1629.
36. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of piogli-
tazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;
355:2297–2307.
37. Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of
pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gas-
troenterology 2008; 135:1176–1184.
38. Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for nonalcoholic
steatohepatitis: one-year results of the randomized placebo-controlled Fatty
Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterol-
ogy 2008; 135:100–110.
39. Lutchman G, Modi A, Kleiner DE, et al. The effects of discontinuing piogli-
tazone in patients with nonalcoholic steatohepatitis. Hepatology 2007;
46:424–429.
40. Mahady SE, Webster AC, Walker S, et al. The role of thiazolidinediones in
nonalcoholic steatohepatitis: a systematic review and meta analysis.
J Hepatol 2011; 55:1383–1390.
41. Murphy CE, Rodgers PT. Effects of thiazolidinediones on bone loss and
fracture. Ann Pharmacother 2007; 41:2014–2018.
42. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of
nonalcoholic fatty liver disease: practice Guideline by the American Associa-
tion for the Study of Liver Diseases, American College of Gastroenterology,
and the American Gastroenterological Association. Hepatology 2012;
55:2005–2023.
43. Parola M, Muraca R, Dianzani I, et al. Vitamin E dietary supplementation
inhibits transforming growth factor beta 1 gene expression in the rat liver.
FEBS Lett 1992; 308:267–270.
44. Houglum K, Venkataramani A, Lyche K, et al. A pilot study of the effects of
d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C.
Gastroenterology 1997; 113:1069–1073.
45. Morante M, Sandoval J, Gomez-Cabrera MC, et al. Vitamin E deficiency
induces liver nuclear factor-kappaB DNA-binding activity and changes in
related genes. Free Radic Res 2005; 39:1127–1138.
46. Soden JS, Devereaux MW, Haas JE, et al. Subcutaneous vitamin E amelio-
rates liver injury in an in vivo model of steatocholestasis. Hepatology 2007;
46:485–495.
47. Sokol RJ, McKim JM Jr, Goff MC, et al. Vitamin E reduces oxidant injury to
mitochondria and the hepatotoxicity of taurochenodeoxycholic acid in the rat.
Gastroenterology 1998; 114:164–174.
48. Sanyal AJ, Mofrad PS, Contos MJ, et al. A pilot study of vitamin E versus
vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis.
Clin Gastroenterol Hepatol 2004; 2:1107–1115.
49. Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of
prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial
(SELECT). J Am Med Assoc 2011; 306:1549–1556.
50. Schurks M, Glynn RJ, Rist PM, et al. Effects of vitamin E on stroke subtypes:
meta-analysis of randomised controlled trials. BMJ 2010; 341:c5702.
51. Lin HZ, Yang SQ, Chuckaree C, et al. Metformin reverses fatty liver disease in
obese, leptin-deficient mice. Nat Med 2000; 6:998–1003.
52. Torres DM, Jones FJ, Shaw JC, et al. Rosiglitazone versus rosiglitazone and
metformin versus rosiglitazone and losartan in the treatment of nonalcoholic
steatohepatitis in humans: a 12-month randomized, prospective, open-label
trial. Hepatology 2011; 54:1631–1639.
53. Loomba R, Lutchman G, Kleiner DE, et al. Clinical trial: pilot study of
metformin for the treatment of nonalcoholic steatohepatitis. Aliment Phar-
macol Ther 2009; 29:172–182.
54. Chalasani N, Aljadhey H, Kesterson J, et al. Patients with elevated liver
enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology
2004; 126:1287–1292.
55. Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for
treatment of nonalcoholic steatohepatitis: results of a randomized trial.
Hepatology 2004; 39:770–778.
56. Oakley F, Teoh V, Ching ASG, et al. Angiotensin II activates I kappaB kinase
phosphorylation of RelA at Ser 536 to promote myofibroblast survival and
liver fibrosis. Gastroenterology 2009; 136:2334–2344. Copyright © 2015 Wolters Kluwer 
182 www.co-gastroenterology.com57. Koppe SW, Sahai A, Malladi P, et al. Pentoxifylline attenuates steatohepatitis
induced by the methionine choline deficient diet. J Hepatol 2004; 41:592–
598.
58. Preaux AM, Mallat A, Rosenbaum J, et al. Pentoxifylline inhibits growth and
collagen synthesis of cultured human hepatic myofibroblast-like cells. He-
patology 1997; 26:315–322.
59. US National Library of Medicine. Safety, tolerability, pharmacokinetics and
activity of GS-9450 in adults with non-alcoholic steatohepatitis (NASH).
2014. https://clinicaltrials.gov/ct2/show/NCT00740610?term=GS-9450&
rank=2. [Accessed 28 January 2015]
60. US National Library of Medicine. Phase IIb study to evaluate the efficacy
and safety of GFT505 versus placebo in patients with non-alcoholic stea-
tohepatitis (NASH). 2015. https://clinicaltrials.gov/ct2/show/NCT0169
4849?term=GFT-505&rank=4. [Accessed 28 January 2015]
61. US National Library of Medicine. The farnesoid X receptor (FXR) ligand
obeticholic acid in NASH treatment trial (FLINT). 2014. https://clinicaltrials.
gov/ct2/show/NCT01265498?term=obeticholic+acid&rank=1. [Accessed
28 January 2015]
62. US National Library of Medicine. Efficacy and safety study of cenicriviroc for
the treatment of NASH in adult subjects with liver fibrosis (CENTAUR). 2014.
https://clinicaltrials.gov/ct2/show/NCT02217475?term=cenicriviroc&rank
=5. [Accessed 28 January 2015]
63. US National Library of Medicine. Liraglutide efficacy and action in non-
alcoholic steatohepatitis (LEAN). 2013. https://clinicaltrials.gov/ct2/show/
NCT01237119?term=liraglutide+NAFLD&rank=3. [Accessed 28 January
2015]
64. US National Library of Medicine. Sitagliptin versus placebo in the treatment
of nonalcoholic fatty liver disease. 2013. https://clinicaltrials.gov/ct2/show/
NCT01963845?term=sitagliptin+NASH&rank=2. [Accessed 28 January
2015]
65. US National Library of Medicine. Simtuzumab (GS-6624) in the treatment of
cirrhosis due to NASH. 2014. https://clinicaltrials.gov/ct2/show/NCT0167
2879?term=simtuzumab+NASH&rank=1. [Accessed 28 January 2015]
66. US National Library of Medicine. Safety and efficacy of simtuzumab (GS-
6624) in adults with advanced liver fibrosis but not cirrhosis secondary to
non-alcoholic steatohepatitis (NASH). 2014. https://clinicaltrials.gov/ct2/
show/NCT01672866?term=simtuzumab+NASH&rank=2. [Accessed 28
January 2015]
67. Anstee QM, Concas D, Kudo H, et al. Impact of pan-caspase inhibition in
animal models of established steatosis and nonalcoholic steatohepatitis.
J Hepatol 2010; 53:542–550.
68. Ratziu V, Sheikh MY, Sanyal AJ, et al. A phase 2, randomized, double-blind,
placebo-controlled study of GS-9450 in subjects with nonalcoholic steato-
hepatitis. Hepatology 2012; 55:419–428.
69.
&
Staels B, Rubenstrunk A, Noel B, et al. Hepatoprotective effects of the dual
peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in
rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepa-
titis. Hepatology 2013; 58:1941–1952.
GFT-505 improves liver enzymes (ALT, g-glutamyl transferase, alkaline phospha-
tase) in insulin-resistant patients.
70. Cariou B, Zair Y, Staels B, et al. Effects of the new dual PPAR alpha/delta
agonist GFT505 on lipid and glucose homeostasis in abdominally obese
patients with combined dyslipidemia or impaired glucose metabolism. Dia-
betes Care 2011; 34:2008–2014.
71. Cariou B, Hanf R, Lambert-Porcheron S, et al. Dual peroxisome proliferator-
activated receptor alpha/delta agonist GFT505 improves hepatic and per-
ipheral insulin sensitivity in abdominally obese subjects. Diabetes Care 2013;
36:2923–2930.
72. Wagner M, Zollner G, Trauner M. Nuclear bile acid receptor farnesoid X
receptor meets nuclear factor-kappaB: new insights into hepatic inflamma-
tion. Hepatology 2008; 48:1383–1386.
73. Wang YD, Chen WD, Wang M, et al. Farnesoid X receptor antagonizes
nuclear factor kappaB in hepatic inflammatory response. Hepatology 2008;
48:1632–1643.
74. Zhang S, Wang J, Liu Q, et al. Farnesoid X receptor agonist WAY-362450
attenuates liver inflammation and fibrosis in murine model of nonalcoholic
steatohepatitis. J Hepatol 2009; 51:380–388.
75.
&
Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X
receptor agonist obeticholic acid in patients with type 2 diabetes
and nonalcoholic fatty liver disease. Gastroenterology 2013; 145:574–
582.
Proof-of-concept study testing FXR agonist in patients with type 2 diabetes
mellitus and NAFLD.
76.
&&
Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear
receptor ligand obeticholic acid for noncirrhotic, nonalcoholic steatohepatitis
(FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2014.
DOI: http://dx.doi.org/10.1016/S0140-6736(14)61933-4.
Obeticholic acid is one of the first agents where robust, beneficial changes in liver
histology have been identified in patients with NASH.
77. Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet
Oncol 2002; 3:565–574.
78. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and
mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J
Med 2003; 348:1625–1638.Health, Inc. All rights reserved.
Volume 31  Number 3  May 2015
Nonalcoholic fatty liver disease Hardy et al.79. El-Serag HB, Hampel H, Javadi F. The association between diabetes and
hepatocellular carcinoma: a systematic review of epidemiologic evidence.
Clin Gastroenterol Hepatol 2006; 4:369–380.
80. Abdelmalek MF, Diehl AM. Nonalcoholic fatty liver disease as a complication
of insulin resistance. Med Clin North Am 2007; 91:1125–1149.
81. Valenti L, Al-Serri A, Daly AK, et al. Homozygosity for the patatin-like
phospholipase-3/adiponutrin I148 M polymorphism influences liver fibrosis
in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51:1209–
1217.
82.
&
Liu YL, Patman GL, Leathart JB, et al. Carriage of the PNPLA3 rs738409 C
> G polymorphism confers an increased risk of nonalcoholic fatty liver
disease associated hepatocellular carcinoma. J Hepatol 2014; 61:75–
81.
The polymorphism conferring progressive NAFLD also increases the risk of
NAFLD-HCC.
83. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in nonalcoholic
fatty liver disease: an emerging menace. J Hepatol 2012; 56:1384–
1391.
84. Dyson J, Jaques B, Chattopadyhay D, et al. Hepatocellular cancer: the impact
of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 2014;
60:110–117.
85. Yasui K, Hashimoto E, Komorizono Y, et al. Characteristics of patients with
nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin
Gastroenterol Hepatol 2011; 9:428–433.
86. Guzman G, Brunt EM, Petrovic LM, et al. Does nonalcoholic fatty liver disease
predispose patients to hepatocellular carcinoma in the absence of cirrhosis?
Arch Pathol Lab Med 2008; 132:1761–1766.
87. Sanyal A, Poklepovic A, Moyneur E, et al. Population-based risk factors and
resource utilization for HCC: US perspective. Curr Med Res Opin 2010;
26:2183–2191.
88. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;
444:860–867.
89. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009;
50:957–969.
90. Unger RH, Clark GO, Scherer PE, et al. Lipid homeostasis, lipotoxicity
and the metabolic syndrome. Biochim Biophys Acta 2010; 1801:209–
214.
91. Ohlsson C, Mohan S, Sjogren K, et al. The role of liver-derived insulin-like
growth factor-I. Endocr Rev 2009; 30:494–535.
92. Chen HP, Shieh JJ, Chang CC, et al. Metformin decreases hepatocellular
carcinoma risk in a dose-dependent manner: population-based and in vitro
studies. Gut 2013; 62:606–615.
93. Nkontchou G, Cosson E, Aout M, et al. Impact of metformin on the prognosis
of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol
Metab 2011; 96:2601–2608. Copyright © 2015 Wolters Kluwe
0267-1379 Copyright  2015 Wolters Kluwer Health, Inc. All rights rese94. Donadon V, Balbi M, Mas MD, et al. Metformin and reduced risk of hepa-
tocellular carcinoma in diabetic patients with chronic liver disease. Liver Int
2010; 30:750–758.
95. Zhang ZJ, Zheng ZJ, Shi R, et al. Metformin for liver cancer prevention in
patients with type 2 diabetes: a systematic review and meta-analysis. J Clin
Endocrinol Metab 2012; 97:2347–2353.
96. Shachaf CM, Kopelman AM, Arvanitis C, et al. MYC inactivation uncovers
pluripotent differentiation and tumour dormancy in hepatocellular cancer.
Nature 2004; 431:1112–1117.
97. Cao Z, Fan-Minogue H, Bellovin DI, et al. MYC phosphorylation, activation,
and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-
CoA reductase. Cancer Res 2011; 71:2286–2297.
98. Demierre MF, Higgins PD, Gruber SB, et al. Statins and cancer prevention.
Nat Rev Cancer 2005; 5:930–942.
99. Wu J, Wong WW, Khosravi F, et al. Blocking the Raf/MEK/ERK pathway
sensitizes acute myelogenous leukemia cells to lovastatin-induced apopto-
sis. Cancer Res 2004; 64:6461–6468.
100. Marcelli M, Cunningham GR, Haidacher SJ, et al. Caspase-7 is activated
during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP.
Cancer Res 1998; 58:76–83.
101.
&
Singh S, Singh PP, Singh AG, et al. Statins are associated with a reduced
risk of hepatocellular cancer: a systematic review and meta-analysis. Gastro-
enterology 2013; 144:323–332.
Meta-analysis of seven observational studies and three studies reporting pooled
data from 26 RCTs.
102. Liu X, Lazenby AJ, Clements RH, et al. Resolution of nonalcoholic steato-
hepatits after gastric bypass surgery. Obes Surg 2007; 17:486–492.
103. BarkerKB, Palekar NA,Bowers SP,et al.Nonalcoholic steatohepatitis: effect of
Roux-en-Y gastric bypass surgery. Am J Gastroenterol 2006; 101:368–373.
104. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, et al. Bariatric
surgery for nonalcoholic steatohepatitis in obese patients. Cochrane Data-
base Syst Rev 2010; (1):CD007340.
105. Taitano AA, Markow M, Finan JE, et al. Bariatric surgery improves histological
features of nonalcoholic fatty liver disease and liver fibrosis. J Gastrointest
Surg 2014. doi: http://dx.doi.org/10.1007/s11605-014-2678-y.
106. Mathurin P, Hollebecque A, Arnalsteen L, et al. Prospective study of the long-
term effects of bariatric surgery on liver injury in patients without advanced
disease. Gastroenterology 2009; 137:532–540.
107. Anstee QM, Day CP. The genetics of NAFLD. Nat Rev Gastroenterol Hepatol
2013; 10:645–655.
108.
&&
Liu YL, Reeves HL, Burt AD, et al. TM6SF2 rs58542926 influences hepatic
fibrosis progression in patients with nonalcoholic fatty liver disease. Nat
Commun 2014; 5:4309.
The first report demonstrating an association between TM6SF2 variant and fibrosis
in NAFLD.r Health, Inc. All rights reserved.
rved. www.co-gastroenterology.com 183
